Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network

We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963...

Full description

Bibliographic Details
Authors: Rose, Angela Mc, Pozo Sanchez, Francisco, Martínez-Baz, Iván, Mazagatos, Clara, Bossuyt, Nathalie, Cauchi, John Paul, Petrović, Goranka, Loghin, Isabela I, Vaikutytė, Roberta, Buda, Silke, Machado, Ausenda, Duffy, Róisín, Oroszi, Beatrix, Howard, Jennifer, Echeverria, Aitziber, Andreu, Cristina, Barbezange, Cyril, Džiugytė, Aušra, Nonković, Diana, Popescu, Corneliu-Petru, Majauskaite, Fausta, Tolksdorf, Kristin, Gomez, Verónica, Domegan, Lisa, Horváth, Judit Krisztina, Castilla, Jesús, García, Miriam, Demuyser, Thomas, Borg, Maria-Louise, Tabain, Irena, Lazar, Mihaela, Kubiliute, Ieva, Dürrwald, Ralf, Guiomar, Raquel, O'Donnell, Joan, Kristóf, Katalin, Nicolay, Nathalie, Bacci, Sabrina, Kissling, Esther, EBIS SARI VE network team
Format: article
Publication Date:2024
Country:España
Institution:Instituto de Salud Carlos III (ISCIII)
Repository:Repisalud
Language:English
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/19060
Online Access:http://hdl.handle.net/20.500.12105/19060
Access Level:Open access
Keyword:Influenza, Human
Influenza A Virus, H1N1 Subtype
Influenza Vaccines
Pneumonia
Adult
Humans
Seasons
Influenza A Virus, H3N2 Subtype
Case-Control Studies
Vaccine Efficacy
Europe
Hospitalization
Hospitals
Vaccination
Description
Summary:We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI: -23-36); 20% (95% CI: -4-39) against A(H3N2) and 56% (95% CI: 22-75) against B. During the 2022/2023 season, while VE against hospitalisation with influenza B was >55%, it was ≤20% for influenza A subtypes. While influenza vaccination should be a priority for future seasons, improved vaccines against influenza are needed.

Similar Items